Novo

Novo Oil & Gas II Receives Equity Capital Commitment from EnCap Investments

Retrieved on: 
星期二, 四月 23, 2024
Energy, Professional Services, Oil, Gas, Finance, Permian, Investment, Novo, Delaware Basin, Partnership, Acquisition, EnCap Investments

Novo Oil & Gas today announced the launch of Novo Oil & Gas Holdings II, LLC (Novo II) with an equity capital commitment from EnCap Investments .

Key Points: 
  • Novo Oil & Gas today announced the launch of Novo Oil & Gas Holdings II, LLC (Novo II) with an equity capital commitment from EnCap Investments .
  • Novo II intends to pursue both operated and non-operated mineral positions.
  • The Novo II team has worked together for years, as all in-house Novo II employees previously held roles at Novo I.
  • Novo I was acquired by Earthstone Energy, Inc. and Northern Oil and Gas, Inc. in August, 2023, for $1.5 billion.

Upgraded Nunyerry North Drill Results Deliver High-Grade Intercepts Up to 6.12 g/t Au

Retrieved on: 
星期二, 三月 26, 2024
Diamond, Well, NVO, Vein, Gold, ASX, Creasy, RC, Novo, Igneous intrusion, Anomaly, Outline, Estrid, TSX, IP, Aegina, Clutch (eggs), Soil, Rehabilitation, Mining

VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce updated, high-grade results from the maiden reverse circulation (RC) drill program completed at Nunnery North in late 2023.

Key Points: 
  • Significant drill intercepts from the 2023 Nunyerry North program of shallow reverse circulation drilling were re-analysed by multi-pot PhotonAssay™.
  • Commenting on the high-grade results from Nunyerry North, Novo Executive Co-Chairman and Acting CEO Mike Spreadborough said
    “It is exciting to see a significant grade increase in the Nunyerry North drill results, some of which are close to surface and demonstrate the substantial upside potential of this Project.
  • Based on the results, Novo resubmitted all significant drill intercepts for multi-pot PhotonAssay™ whereby all sample material was split over multiple PhotonAssay™ pots.
  • Figure 3: Nunyerry North geological interpretation, 2023 drill hole location and new drill target areas.

TDConnex completes spinout investment and emerges as a new global manufacturing company

Retrieved on: 
星期三, 四月 3, 2024
Principal, Growth, Partner (business rank), Partnership, Stock exchange, Acquisition, Novo, TDG, System, Airline

SINGAPORE, April 3, 2024 /PRNewswire/ -- TDConnex, a leading global precision manufacturing business, announced today that it has become an independent, Singapore-based company following its acquisition by Novo Tellus and 65 Equity Partners.

Key Points: 
  • SINGAPORE, April 3, 2024 /PRNewswire/ -- TDConnex, a leading global precision manufacturing business, announced today that it has become an independent, Singapore-based company following its acquisition by Novo Tellus and 65 Equity Partners.
  • Tan Chong Lee, CEO of 65 Equity Partners said: "65 Equity Partners is pleased to be backing Singapore-headquartered TDConnex and its management team in its continued pursuit of manufacturing excellence to serve global technology leaders.
  • We look forward to working alongside Novo Tellus to support TDConnex as it continues to grow on a global scale."
  • CEO of TDConnex, Thanga Venkatachalam concluded: "today marks a historic milestone for TDConnex.

TDConnex completes spinout investment and emerges as a new global manufacturing company

Retrieved on: 
星期三, 四月 3, 2024
Principal, Growth, Partner (business rank), Partnership, Stock exchange, Acquisition, Novo, TDG, System, Airline

SINGAPORE, April 3, 2024 /PRNewswire/ -- TDConnex, a leading global precision manufacturing business, announced today that it has become an independent, Singapore-based company following its acquisition by Novo Tellus and 65 Equity Partners.

Key Points: 
  • SINGAPORE, April 3, 2024 /PRNewswire/ -- TDConnex, a leading global precision manufacturing business, announced today that it has become an independent, Singapore-based company following its acquisition by Novo Tellus and 65 Equity Partners.
  • Tan Chong Lee, CEO of 65 Equity Partners said: "65 Equity Partners is pleased to be backing Singapore-headquartered TDConnex and its management team in its continued pursuit of manufacturing excellence to serve global technology leaders.
  • We look forward to working alongside Novo Tellus to support TDConnex as it continues to grow on a global scale."
  • CEO of TDConnex, Thanga Venkatachalam concluded: "today marks a historic milestone for TDConnex.

2023 Novo Holdings Bioindustrial Investments Team Annual Review/Business Update

Retrieved on: 
星期五, 三月 15, 2024
Health, Biotechnology, Agriculture, Fungus, Biofuel, Climate, Novo, Investment, CHR, Partnership, Novozymes

Made substantial investments, solidifying Novo Holdings' position as one of the world's foremost active investors in the bioindustrial sector.

Key Points: 
  • Made substantial investments, solidifying Novo Holdings' position as one of the world's foremost active investors in the bioindustrial sector.
  • COPENHAGEN, Denmark, March 15, 2024 /PRNewswire/ -- Novo Holdings Bioindustrial Investments team today publishes its review of 2023 – paving the way for a more sustainable future.
  • Novo Holdings Bioindustrial Investments team understands that radical innovation is needed if we are to win the battle against global warming and its damaging effects on the health of people and the planet.
  • The Bioindustrial Investments team remains steadfast on harnessing the power of biotechnology to deliver impactful solutions for both industry and agriculture.

2023 Novo Holdings Bioindustrial Investments Team Annual Review/Business Update

Retrieved on: 
星期五, 三月 15, 2024
Health, Biotechnology, Agriculture, Fungus, Biofuel, Climate, Novo, Investment, CHR, Partnership, Novozymes

Made substantial investments, solidifying Novo Holdings' position as one of the world's foremost active investors in the bioindustrial sector.

Key Points: 
  • Made substantial investments, solidifying Novo Holdings' position as one of the world's foremost active investors in the bioindustrial sector.
  • COPENHAGEN, Denmark, March 15, 2024 /PRNewswire/ -- Novo Holdings Bioindustrial Investments team today publishes its review of 2023 – paving the way for a more sustainable future.
  • Novo Holdings Bioindustrial Investments team understands that radical innovation is needed if we are to win the battle against global warming and its damaging effects on the health of people and the planet.
  • The Bioindustrial Investments team remains steadfast on harnessing the power of biotechnology to deliver impactful solutions for both industry and agriculture.

Ashland drives gender parity, shines spotlight on the inspirational power of women from lab bench to real life, and announces Responsible Solvers™ speaker series

Retrieved on: 
星期五, 三月 8, 2024
Engineering, International, Woman, Student, Ethics, Craig Gardner, Novo, Ashland Global, African, Female, ESG, Curriculum, Social exclusion, Safety, Science, Gender, Parity, Partnership, Toy

Ashland also announced its Responsible Solvers™ employee engagement and speaker series for 2024 which includes external and internal speakers.

Key Points: 
  • Ashland also announced its Responsible Solvers™ employee engagement and speaker series for 2024 which includes external and internal speakers.
  • The series also includes information about safety, sustainable sourcing, commercial innovations and more.
  • “Through the Ashland Women’s International Network (AWIN), we are raising the visibility of exceptionally inspirational women,” said Guillermo Novo, chair and chief executive officer, Ashland.
  • Our commitment reinforces Ashland’s passion for STEM, its pervasiveness in our lives, and contributions to our business success,” concluded Novo.

Proposed Board and Leadership Renewal

Retrieved on: 
星期三, 二月 28, 2024
Novo, TSX, Growth, Sale, ASX, NVO, Employment, Management

VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) has commenced a process of Board and Leadership renewal to position the Company for its next phase of growth.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) has commenced a process of Board and Leadership renewal to position the Company for its next phase of growth.
  • As part of this process, it is also proposed that current Non-executive Co-Chairman, Dr Quinton Hennigh will move to the role of Non-Executive Director.
  • Finally, as part of the Board refresh strategy, Non-Executive Director Mr Michael Barrett has advised the Company that he will retire from the Board when a suitable replacement director with appropriate finance experience is appointed.
  • It is anticipated that the Board refresh and leadership transition outlined above will be completed prior to the Company’s Annual General Meeting expected to be scheduled for June 2024.

Nalu Medical, Inc. Closes $85 Million Series E Round

Retrieved on: 
星期二, 三月 5, 2024
Neurology, Biotechnology, Nanotechnology, Surgery, Health, Medical Devices, Health Technology, Technology, Pura, Medicine, Neuropathic pain, PNS, General partnership, Physician, Novo, Spinal cord stimulator, Standard of care, Health care, Chronic pain, Patient, SCS

Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.

Key Points: 
  • Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.
  • Series E was led by Novo Holdings (Novo) with $65M of the total closing in late-December 2023.
  • Also participating in the round were all existing significant investors: Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners.
  • “The Nalu Team is committed to addressing the unmet needs of patients suffering from chronic intractable neuropathic pain.

Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd.

Retrieved on: 
星期三, 二月 21, 2024
Health, Surgery, Medical Supplies, Medical Devices, Consultant, MD, Novo, FDA, U.S. FDA, Hope, MBA, Bone wax, Clinical, Patient, CCI, Agreement, Partnership, Medical device

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International, LLC (“CCI”), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Services Agreement (the “Agreement”), with Futura Surgicare Pvt Ltd (“Futura”), an India-based leading manufacturer of wound closure and surgical products that are marketed and distributed in over 70 countries worldwide under the trade name “Dolphin Sutures”.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International, LLC (“CCI”), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Services Agreement (the “Agreement”), with Futura Surgicare Pvt Ltd (“Futura”), an India-based leading manufacturer of wound closure and surgical products that are marketed and distributed in over 70 countries worldwide under the trade name “Dolphin Sutures”.
  • Futura’s comprehensive and innovative product offering includes surgical sutures, skin staplers, hernia meshes, surgical tapes, hemostats, and bone wax.
  • FDA approval of these high-quality products would symbolize a beacon of hope in addressing the high costs of the American healthcare market.
  • We are confident this partnership will mark a significant milestone in offering affordable and superior surgical solutions."